Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines

Molecular Cancer Therapeutics

Volumn 4, Issue 7, 2005, Pages 1105-1113

  Plasencia, Carmen ^a   Dayam, Raveendra ^a   Wang, Qingcai ^b   Pinski, Jacek ^b   Burke Jr , Terrence R ^c   Quinn, David I ^b   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROTEIN P16; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; SALICYLHYDRAZIDE DERIVATIVE; SC 21; SC 23; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OVARY CANCER; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; TOXICITY TESTING; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; HYDRAZINES; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RETINOBLASTOMA PROTEIN; SALICYLAMIDES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 23144432272     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0288     Document Type: Article

References (31)

1. Neamati N, Barchi JJ Jr. New paradigms in drug design and discovery. Curr Top Med Chem 2002;2:211-27.
2. Hong H, Neamati N, Wang S, et al. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J Med Chem 1997;40:930-6.
3. Zhao H, Neamati N, Sunder S, at al. Hydrazide-containing inhibitors of HIV-1 integrase. J Med Chem 1997;40:937-41.
4. Neamati N, Hong H, Owen JM, et al. Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. J Med Chem 1998;41:3202-9.
5. Neamati N, Lin Z, Karki RG, et al. Metal-dependent inhibition of HIV-1 integrase. J Med Chem 2002;45:5661-70.
6. Fesen MR, Kohn KW, Leteurtre F, Pommier Y. Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci U S A 1993;90: 2399-403.
7. Neamati N, Mazumder A, Sunder S, Lown JW, Pommier Y. Lexitropsins as potent inhibitors of HIV-1 integrase. In Keystone Symposia on Molecular and Cellular Biology; 1997; Santa Fe. Keystone Symposia; 1997. p. 32.
8. Neamati N, Hong H, Sunder S, Milne GW, Pommier Y. Potent inhibitors of human immunodeficiency virus type 1 integrase: identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Mol Pharmacol 1997;52:1041-55.
9. Neamati N, Hong H, Mazumder A, et al. Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. J Med Chem 1997;40:942-51.
10. Melek M, Jones JM, O'Dea MH, et al. Effect of HIV integrase inhibitors on the RAG1/2 recombinase. Proc Natl Acad Sci U S A 2002;99: 134-7.
11. Neamati N, Marchand C, Pommier Y. HIV-1 integrase inhibitors: past, present, and future. Adv Pharmacol 2000;49:147-65.
12. Rice P, Craigie R, Davies DR. Retroviral integrases and their cousins. Curr Opin Struct Biol 1996;6:76-83.
13. Buick RN, Pullano R, Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985;45:3668-76.
14. Hamaguchi K, Godwin AK, Yakushiji M, et al. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 1993;53:5225-32.
15. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42.
16. Fadok VA, Voelker DR, Campbell PA, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992;148: 2207-16.
17. Egan WJ, Merz KM Jr, Baldwin JJ. Prediction of drug absorption using multivariate statistics. J Med Chem 2000;43:3867-77.
18. Egan WJ, Lauri G. Prediction of intestinal permeability. Adv Drug Deliv Rev 2002;54:273-89.
19. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery. Adv Drug Deliv Rev 1997;23:3-25.
20. Palm K, Luthman K, Ungell AL, et al. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J Med Chem 1998;41: 5382-92.
21. Palm K, Stenberg P, Luthman K, Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 1997;14:568-71.
22. Palm K, Luthman K, Ungell AL, Strandlund G, Artursson P. Correlation of drug absorption with molecular surface properties. J Pharm Sci 1996;85:32-9.
23. Kelder J, Grootenhuis PD, Bayada DM, Delbressine LP, Ploemen JP. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 1999;16:1514-9.
24. Clark DE, Grootenhuis PD. Predicting passive transport in silico-history, hype, hope. Curr Top Med Chem 2003;3:1193-203.
25. Zuco V, Supino R, De Cesare M, et al. Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models. Biochem Pharmacol 2003;65:1281-94.
26. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980;77:1561-5.
27. Lanzi C, Cassinelli G, Cuccuru G, et al. Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. Prostate 2001;48:254-64.
28. Sun SY, Hail N Jr, Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 2004;96:662-72.
29. Assuncao Guimaraes C, Linden R. Programmed cell deaths. Apoptosis and alternative deathstyles. Eur J Biochem 2004;271:1638-50.
30. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49.
31. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004;23:2797-808.